DMN:FRA
Diamyd Medical AB
€0.064
arrow_upward
+1.92%(+0.0012) 1D
Nov 20, 8:04:51 AM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
€0.06
High
€0.06
Low
€0.06
Mkt. cap
136.78M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.80
52-wk low
€0.05
No. of employees
42
Open
€0.06
High
€0.06
Low
€0.06
Mkt. cap
136.78M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.80
52-wk low
€0.05
No. of employees
42
News stories
From web sources and news partners
The Motley Fool
·
1 hour ago
Nvidia Has Lost More Than the Market Value of 495 S&P 500 Companies in 6 Weeks -- and Its Downtrend May Be Just Beginning
MarketWatch
·
11 minutes ago
Here’s what happened next after previous times the S&P 500 losing streak reached six sessions
MarketForces Africa
·
1 hour ago
S&P 500, Nasdaq, Dow Jones Dip Amidst Anthropic IPO Debut
Investing.com
·
2 hours ago
S&P 500 Breaks Support as Global Risk Sentiment Begins to Crack
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB
CEOUlf Hannelius
Employees42
Founded1984
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitediamyd.com